Sort   by:  
 Page size 
UnknownMelittin - the main component of bee venom: a promising therapeutic agent for neuroprotection through keap1/Nrf2/HO-1 pathway activation.
Not available
S-EPMC11603938 | biostudies-literature
UnknownLindera obtusiloba Attenuates Oxidative Stress and Airway Inflammation in a Murine Model of Ovalbumin-Challenged Asthma.
Not available
S-EPMC7402094 | biostudies-literature
UnknownDiscontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia.
Not available
S-EPMC8242303 | biostudies-literature
UnknownSafety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
Not available
S-EPMC7955499 | biostudies-literature
UnknownLong-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Not available
S-EPMC6619057 | biostudies-literature
UnknownPost-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Not available
S-EPMC7905790 | biostudies-literature
UnknownConsistent improvement with eculizumab across muscle groups in myasthenia gravis.
Not available
S-EPMC7448154 | biostudies-literature
UnknownEculizumab improves fatigue in refractory generalized myasthenia gravis.
Not available
S-EPMC6620379 | biostudies-literature
Unknown'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Not available
S-EPMC7320935 | biostudies-literature
UnknownBurden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535840 | biostudies-literature
Sort   by:  
 Page size